KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $74.3 million.

  • Acadia Pharmaceuticals' Cash from Operations rose 1745.88% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year decrease of 186.41%. This contributed to the annual value of $157.7 million for FY2024, which is 84431.21% up from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Cash from Operations is $74.3 million, which was up 1745.88% from $64.0 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Cash from Operations ranged from a high of $85.4 million in Q4 2023 and a low of -$76.3 million during Q1 2022
  • Its 5-year average for Cash from Operations is $4.9 million, with a median of -$727000.0 in 2022.
  • Examining YoY changes over the last 5 years, Acadia Pharmaceuticals' Cash from Operations showed a top increase of 45796.51% in 2023 and a maximum decrease of 800935.35% in 2023.
  • Acadia Pharmaceuticals' Cash from Operations (Quarter) stood at -$23.1 million in 2021, then decreased by 3.17% to -$23.9 million in 2022, then soared by 457.97% to $85.4 million in 2023, then crashed by 52.71% to $40.4 million in 2024, then skyrocketed by 83.97% to $74.3 million in 2025.
  • Its Cash from Operations stands at $74.3 million for Q3 2025, versus $64.0 million for Q2 2025 and $20.3 million for Q1 2025.